[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracranial-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracranial-hemorrhage":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100565970",false,"NCT06649097","Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System","CRYSTAL","Inclusion criteria:\n\n* Age \\>=18 years of age\n* Intracranial hemorrhage documented on head CT or MRI scan.\n* Indication for active fluid exchange evaluated by treating physician.\n* Signed informed consent obtained by patient or Legal Authorized Representative\n* Scheduled enrollment and treatment within 72 hours of last known well (LKW)\n\nExclusion criteria:\n\n* GCS ≤ 5\n* Pregnancy\n* Fixed and dilated pupil\n* Life-threatening medical condition","ALL","18 Years",{"count":18,"type":19},250,"ESTIMATED","6 Months","OBSERVATIONAL","The study is a multi-center prospective cohort, controlled, phase 4 post-market registry evaluating the efficacy and radiographic outcomes associated with the use of the IRRAflow® Active Fluid Exchange System compared to standard of care external ventricular drains.",[24,25,26],"Intracranial Hemorrhage","Ventriculitis","Intracranial Abscess","RECRUITING","2025-10-24",{"date":30,"type":31},"2025-10-28","ACTUAL",{"date":33,"type":31},"2025-09-25",{"date":35,"type":19},"2031-07",{"name":37,"class":38},"Christopher P Kellner","OTHER",1,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100599727","NCT07088250","Statins for Treatment of Primary Intracerebral Hemorrhage","Statins for Treatment Of Primary IntraCerebral Hemorrhage (STOP ICH)","STOP ICH","Inclusion Criteria:\n\n* Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT);\n* Age 18-80 years;\n* Hematoma located in the supratentorial region;\n* Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours;\n* Atorvastatin treatment can be initiated within 48 hours of symptom onset or last known well;\n* Glasgow Coma Scale (GCS) score ≥9;\n* Baseline hematoma volume of 5-35 mL;\n* Signed informed consent obtained.\n\nExclusion Criteria:\n\n* ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral venous thrombosis, or anticoagulant-related ICH;\n* Patients who have undergone or are scheduled for immediate surgical intervention;\n* Pregnancy or lactation;\n* Use of oral anticoagulants within 1 month prior to symptom onset;\n* Pre-stroke mRS \\>1;\n* Known allergy to statins, active liver disease, liver dysfunction, or rhabdomyolysis;\n* Known terminal illness with a pre-stroke life expectancy of less than three months, or patients with planned withdrawal of care.","80 Years",{"count":49,"type":19},264,"INTERVENTIONAL",[52],"NA","The STOP ICH trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the efficacy and safety of atorvastatin in patients with intracerebral hemorrhage (ICH) presenting within 3 to 24 hours of symptom onset.",[55,56,24,57],"Cerebrovascular Disorders","Intracranial Hemorrhages","Intracerebral Haemorrhage",[59,60,61,62],"Intracerebral hemorrhage","Treatment","Atorvastatin","Outcome","2025-07-20",{"date":65,"type":31},"2025-07-28",{"date":67,"type":31},"2023-05-06",{"date":69,"type":19},"2026-12-31",{"name":71,"class":38},"The Second Hospital of Anhui Medical University",22,""]